Cargando…

Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1

The incidence of many cancer types is significantly reduced in individuals with Down syndrome1–4 and it is proposed that this broad cancer protection is conferred by the elevated expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21. One such gene is the Down sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Kwan-Hyuck, Zaslavsky, Alexander, Lynch, Ryan C., Britt, Carmella, Okada, Yoshiaki, Siarey, Richard J., Lensch, M. William, Park, In-Hyun, Yoon, Sam S., Minami, Takashi, Reeves, Roger, Korenberg, Julie R., Folkman, Judah, Daley, George Q., Aird, William C., Galdzicki, Zygmunt, Ryeom, Sandra
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724004/
https://www.ncbi.nlm.nih.gov/pubmed/19458618
http://dx.doi.org/10.1038/nature08062
Descripción
Sumario:The incidence of many cancer types is significantly reduced in individuals with Down syndrome1–4 and it is proposed that this broad cancer protection is conferred by the elevated expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21. One such gene is the Down syndrome candidate region-1 (Dscr1, RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signalling via the calcineurin pathway5–10. Here we show that DSCR1 is elevated in Down syndrome individuals and a mouse model of Down syndrome. Further, we show that the modest elevation in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumor growth in mice and that such resistance is a consequence of a deficit in tumor angiogenesis arising from suppression of the calcineurin pathway. We also provide evidence that attenuation of calcineurin activity by DSCR1 together with another chromosome 21 gene DYRK1A, may be sufficient to dramatically diminish angiogenesis. These data provide a mechanism for the reduced cancer incidence in Down syndrome and identifies the calcineurin signalling pathway and its regulators DSCR1 and DYRK1A as potential therapeutic targets in cancers arising in all individuals.